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A Dutch traveller returning from Suriname in early 
March 2017, presented with fever and severe acute 
liver injury. Yellow fever was diagnosed by (q)RT-PCR 
and sequencing. During hospital stay, the patient’s 
condition deteriorated and she developed hepatic 
encephalopathy requiring transfer to the intensive 
care. Although yellow fever has not been reported in 
the last four decades in Suriname, vaccination is rec-
ommended by the World Health Organization for visi-
tors to this country.
Yellow fever virus (YFV) is known to be enzootic in 
South America, causing periodic outbreaks of disease 
in monkeys and humans in some countries. In Brazil, 
there has been an outbreak of yellow fever ongoing 
since December 2016 with 1,500 cases as at 9 March 
[1,2]. Here we report an imported case of human infec-
tion with YFV in a traveller returning from Suriname, on 
the north-eastern coast of South America, from where 
the last case of yellow fever was reported 45 years ago.
Case description
In March 2017, a Dutch Caucasian female in her late 20s 
from the Netherlands was referred to the University 
Medical Center Groningen in the Netherlands because 
of high fever and signs of severe acute liver injury after 
returning from a two-week stay in Suriname. She had 
no co-morbidities apart from obesity (body mass index 
around 40 kg/m2, norm: 18.5–25 kg/m2). During her 
visit she stayed in the capital of Suriname, Paramaribo, 
and she made several daytrips by boat and car, of 
which two in the tropical rainforest (Figure).
She recalled having been bitten by mosquitoes during 
her hike at Brownsberg, a nature resort in the rainfor-
est with wildlife. Before her travel, she did not visit 
a travel clinic and did not receive yellow fever vacci-
nation. On day 12 of her visit in Suriname, she expe-
rienced mild muscle pain, headache and nausea and 
she developed a high-grade fever. She returned to 
the Netherlands on day 15 and visited the emergency 
department of a secondary care centre, from where 
she was referred to our University hospital. At physi-
cal examination she was not icteric. Except for a tem-
perature of 39.9 °C, vital parameters were normal. The 
results of the remaining physical examination were 
unremarkable. Laboratory testing revealed leukope-
nia (leukocytes 0.9x109/L, norm: 4.0–10.0x109/L) 
and massive liver injury (aspartate aminotransferase 
5,787 U/L, norm: <31 U/L; alanine aminotransferase 
4,910 U/L, norm: <34 U/L), with mildly elevated biliru-
bin levels (total bilirubin 20 µmol/L, norm: <17 µmol/L). 
Liver synthesis was impaired as revealed by increased 
clotting times (activated partial thromboplastin time 
(APTT): 49s, norm: 23–33s; prothrombin time (PT): 
26.6s, norm: 9.0–12.0s) and reduced antithrombin 
(49%, norm: 80–120%). Fibrinogen was diminished 
suggestive of diffuse intravascular coagulation. Renal 
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function was normal apart from severe albuminuria 
(up to 22.6 g/24h, norm: 0g/24h). Malaria, viral hepa-
titis (A, B, C, E, Epstein Barr virus, cytomegalovirus, 
herpes simplex virus), dengue, chikungunya and Zika 
were ruled out (Table). Diagnostic tests to exclude lep-
tospirosis performed on day 6 post onset of symptoms 
(dps 6) were inconclusive (Table) and a convalescent 
serum was going to be tested at the time of publica-
tion. Because of the combination of fever, leukopenia, 
thrombocytopenia, liver injury and travel history, yel-
low fever was included in the differential diagnosis. 
Real-time reverse transcriptase PCR (qRT-PCR) was 
positive for YFV in serum taken on dps 3. On dps 7 the 
patient’s condition deteriorated due to hepatic enceph-
alopathy (ammonia 149 µmol/L, norm: 15–45 µmol/L). 
Cerebral oedema and bleeding was ruled out by com-
puted tomography (CT)-scan. The patient was trans-
ferred to the intensive care unit for close observation of 
vital parameters. Vitamin K was administered. Hepatic 
encephalopathy was treated with rifaximin and lactu-
lose. Ceftriaxone (2g per day intravenously) was given 
for 7 days as antibiotic prophylaxis. Consequently, pos-
sible leptospirosis was also treated. Her neurological 
condition stabilised on dps 10 together with the coag-
ulation parameters. On dps 13 the patient was trans-
ferred back to the ward.
Virology findings
qRT-PCR and/or pan-flavivirus RT-PCR on blood sam-
ples on dps 3 did not detect chikungunya virus (CHIKV), 
dengue virus (DENV), or Zika virus (ZIKV) (Table) [3,4]. 
In four consecutive samples of dps 3–6, YFV-RNA was 
detected (Figure) [4-6], with increasing Ct values (from 
23 to 31 from dps 3 to dps 5 [5] and 39 on dps 6 [6]). 
Sequencing of a 176 bp pan-flavivirus hemi-nested 
RT-PCR product, targeting part of the NS5 genomic 
region confirmed YFV infection [4]. The sequence was 
deposited in the GenBank database under the follow-
ing accession number: KY774973.
On dps 3, indirect immunofluorescence assays (IFA) 
was negative for IgM and IgG against YFV (Flavivirus 
Mosaic, Euroimmun AG, Luebeck, Germany). A conva-
lescent sample of dps 6 was clearly positive for YFV IgM 
(titre 1:10, Figure), with non-reactive IgG. This anti-YFV 
IgM response on dps 6 is in line with literature stat-
ing that IgM antibodies usually appear during the first 
week of illness. Neutralising IgG antibodies are likely to 
appear towards the end of the first week after onset of 
illness and will be tested for in convalescent serum [7].
Background
YFV is a mosquito-borne virus in the genus Flavivirus, 
family Flaviviridae, related to DENV, ZIKV, tick-borne 
encephalitis virus and West Nile virus. YFV is main-
tained in a sylvatic cycle between non-human primates 
and so-called ‘jungle’-mosquitoes (Hemagogus and 
Sabethes spp. in South America) [8]. Sporadic infection 
of humans with sylvatic YFV can occur when unpro-
tected humans are exposed while entering the habitats 
where the viruses circulate. Subsequent introduction 
of a viraemic human case to urban areas with high pop-
ulation densities and Aedes aegypti mosquitoes can 
initiate an urban transmission cycle [9]. YFV is endemic 
in (sub)tropical areas of South America and Africa. The 
risk for YFV infection in South America is the highest in 
tropical regions and during the rainy season (January–
May) when mosquito population densities peak [10]. 
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In 2011, Suriname was identified by the World Health 
Organization (WHO) as one of 14 South American coun-
tries at risk for YFV transmission based on current or 
historic reports of yellow fever, plus the presence of 
competent mosquito vectors and animal reservoirs [11].
Since December 2016, an outbreak of sylvatic YFV is 
ongoing in Brazil; as at 9 March 2017, there were 371 
confirmed and 966 suspected human cases, while a 
total of 968 epizootics in non-human primates have 
been reported, of which 386 were confirmed [2]. So far, 
there has been no evidence for a change from sylvatic 
to an urban transmission cycle [1]. In addition, Bolivia, 
Colombia and Peru have reported suspected and con-
firmed yellow fever cases in 2017 [2].
A subclinical infection with YFV is believed to occur in 
most infected people. In symptomatic cases, symptoms 
of general malaise occur after an incubation period 
of 3–6 days (range 2–9 days), followed by remission 
of the disease in the majority of patients. However, 
15-25% of symptomatic persons develop a complicated 
course of illness, in which symptoms recur after 24–48 
hours, with a reported mortality of 20-60% [7,12]. This 
phase is characterised by fever, abdominal symptoms, 
severe hepatic dysfunction and jaundice, multi-organ 
failure and haemorrhagic diathesis. As no specific anti-
viral treatment is currently available, treatment con-
sists of supportive care [7,12].
Discussion
Although Suriname is considered to be endemic for 
YFV, no human cases have been officially reported 
since 1971 [13]. With a population of ca 570,000 people, 
Suriname has a YFV vaccination coverage of 80–85% 
in infants [14]. Although WHO recommends vaccination 
for travellers to countries with risk of YFV transmission 
like Suriname, sporadic cases of imported yellow fever 
in returning travellers have been reported for exam-
ple in Europe, the United States and Asia [15-17], with 
three reported cases related to the ongoing YFV out-
breaks in South America in European travellers since 
2016 [18,19]. The establishment of ongoing YFV circu-
lation in Suriname extends the current YFV activity in 
South America to five countries [2]. However, despite 
the presence of competent Ae. albopictus mosquitoes 
in France [20] and Ae. aegypti in Madeira, the risk for 
YFV transmission in Europe is currently considered to 
be very low due to the lack of vector activity [18]. An 
effective, safe live-attenuated YFV vaccine is avail-
able for people aged ≥ 9 months and offers lifelong 
immunity [7]. Vaccination is advised by the WHO for 
all travellers to Suriname, for the coastal area as well 
as the inlands [21]. With regard to yellow fever, pre-
travel health advice should take into account destina-
tion, duration of travel, season and the likelihood of 
exposure to mosquitoes (in rural areas, forests versus 
urban areas), and potential contraindications for vac-
cination with a live-attenuated vaccine.
The multi-country YFV activity might reflect current, 
wide-spread ecological conditions that favour elevated 
YFV transmissibility among wildlife and spill-over to 
humans. Thorough sequence analysis of currently cir-
culating strains in Brazil, Bolivia, Colombia, Peru and 
Suriname should provide insight whether the human 
cases in these countries are epidemiologically linked 
or represent multiple, independent spill-over events 
without extensive ongoing community transmission. 
Because of its potential public health impact, our 
case of yellow fever was notified to the WHO and the 
European Union Early Warning and Response System 
on 9 March 2017, according to the international health 
regulations [22].
Table
Pathogens for which laboratory tests were performed, yellow fever case, the Netherlands, March 2017
Pathogen Blood (day 3 post onset of symptoms)
Plasmodium spp. Thick smear negative, antigen test negative
Hepatitis A virus IgM and IgG negative
Hepatitis B virus Serological screening negative
Hepatitis C virus Serological screening negative
Hepatitis E virus PCR negative
Epstein Barr virus IgM and IgG negative
Cytomegalovirus IgM and IgG negative
Herpes simplex virus type 1 and 2 PCR negative
Dengue virus PCR negative, IgM and IgG negative
Chikungunya virus PCR negative, IgM and IgG negative
Zika virus PCR negative, IgM and IgG negativea
Leptospira spp. PCR negative, microscopic agglutination test negative, IgM 1:80b
a Performed on day 5 post onset of symptoms (dps 5).
b ELISA (in-house ELISA Dutch Leptospirosis Reference Center) performed on dps 6 showed IgM 1:80 (cut-off positive IgM ≥1:160). IgM results 
were negative on dps 3 and dps 7 using Leptocheck-WB (Zephyr Biomedicals, Goa, India).
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Conclusion
Clinicians in non-endemic countries should be aware 
of yellow fever in travellers presenting with fever, jaun-
dice and/or haemorrhage returning from South America 
including Suriname. This case report illustrates the 
importance of maintaining awareness of the need for 
YFV vaccination, even for countries with risk of YFV 
transmission that have not reported cases for decades.
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